Skip to content
DataLookout
Start free
Menu

NCT07757204

An Open-label Long-term Safety Study of Buntanetap in Participants With AD

StatusNot Yet Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Start date: Sep 21, 2026 to Nov 21, 2026
    • Eligibility criteria expanded, about 17 words
    • Trial sites expanded: 0 → 14 locations
    • Interventions: buntanetap/posiphen (Drug) to buntanetap/posiphen (Drug)
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Safety of buntanetap
Timeframe: 24 months of treatment
Adverse Events (AE)
Timeframe: 24 months of study
Treatment Emergent Adverse Events (TEAE)
Timeframe: 24 months of study
Serious Adverse Events (SAE)
Timeframe: 24 months of study

Arms and interventions

Single ArmExperimental

All participants receive buntanetap 30 mg qd

Drugs: buntanetap/posiphen

Sites

14 sites in 1 country